Evidence map›Paper›PMID 17929011›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2008

(123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma.

David Loose, Alberto Signore, Ludovicus Staelens, Katia Vanden Bulcke, Hubert Vermeersch, Rudi Andre Dierckx, Elena Bonanno, Christophe Van de Wiele

Open access · greenAbstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. [European journal of nuclear medicine and molecular imaging · 2025
    Article
  2. Article
  3. EJNMMI research · 2025
    Article
  4. Review
  5. Review
  6. Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Article
  7. Review
  8. Clinical-grade N-(4-[EJNMMI radiopharmacy and chemistry · 2019
    Article
  9. Review
  10. Oncotarget · 2018
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

David LooseDepartment of Head and Neck Surgery, Ghent University Hospital, Ghent, Belgium.
Alberto Signore
Ludovicus Staelens
Katia Vanden Bulcke
Hubert Vermeersch
Rudi Andre Dierckx
Elena Bonanno
Christophe Van de Wiele
Ghent University Hospital · BEUniversity Medical Center Groningen · NLUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInformation obtained on the IL-2 receptor status of tumour infiltrating lymphocytes in patients suffering from squamous cell carcinoma of the head and neck (SSCHN) before and after IL-2 treatment may lead to a better understanding of the immunological changes and related kinetics induced at the tumour level and ultimately to a strategy that allows selection of those patients that will benefit from IL-2 therapy. This study set out to assess the relationship between (123)I-IL2 single-photon emission computed tomography (SPECT) findings and the presence of IL-2 receptors (CD25 staining) on tumour-infiltrating lymphocytes as well as on SCCHN tumour cells in patients suffering from SCCHN. MATERIALS AND

methodsSeventeen consecutive patients (12 men; mean age, 57 years) highly suspected to suffer from SSCHN were prospectively included in the study. All patients underwent planar and whole body (123)I-IL2 scintigraphy and underwent surgery or had a biopsy taken within 1 week from imaging. Surgical resected primary lesions as well as biopsy material from primary tumours were histologically analysed with respect to the presence and intensity of CD25 expression on tumour infiltrating lymphocytes and tumour cells (HSCORE). Tumor-to-background (T/N) ratios of the primary tumour derived from planar and tomographic (123)I-IL2 scintigraphy were related to the results derived from histology.

resultsAll patients suffered from SSCHN. T/N ratios derived from SPECT images were significantly correlated with CD25 lymphocyte HSCOREs (r = 0.66; p = 0.03), but not with CD25 tumour cell HSCOREs.

conclusions(123)I-IL-2 SPECT imaging allows for non-invasive imaging of the relative amount of IL-2 receptors present on tumour infiltrating lymphocytes in SCCHN.

Indexed as

AdultAgedCarcinoma, Squamous CellFemaleHead and Neck NeoplasmsHumansInterleukin-2Iodine RadioisotopesMaleMiddle AgedRadionuclide ImagingRadiopharmaceuticalsRecombinant ProteinsReproducibility of ResultsSensitivity and SpecificityInterleukin-2Iodine RadioisotopesRadiopharmaceuticalsRecombinant Proteins

Identifiers

PMID17929011
OpenAlexW1976610797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.